Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CADL |
---|---|---|
09:32 ET | 1857 | 6.94 |
09:34 ET | 345 | 7.0092 |
09:36 ET | 8675 | 7.03 |
09:45 ET | 710 | 6.975 |
09:48 ET | 120 | 6.93 |
09:50 ET | 3161 | 6.81 |
09:52 ET | 2826 | 6.87 |
09:56 ET | 853 | 6.8501 |
10:01 ET | 342 | 6.89 |
10:03 ET | 579 | 6.89 |
10:06 ET | 200 | 6.85 |
10:10 ET | 962 | 6.855 |
10:12 ET | 100 | 6.85 |
10:14 ET | 202 | 6.855 |
10:15 ET | 100 | 6.89 |
10:21 ET | 100 | 6.91 |
10:24 ET | 107 | 6.91 |
10:26 ET | 1563 | 6.86 |
10:28 ET | 100 | 6.89 |
10:33 ET | 539 | 6.889 |
10:42 ET | 5000 | 6.87 |
10:46 ET | 369 | 6.88 |
10:53 ET | 1968 | 6.92 |
11:00 ET | 200 | 6.9638 |
11:04 ET | 700 | 6.98 |
11:06 ET | 300 | 7 |
11:08 ET | 100 | 7 |
11:09 ET | 197 | 6.98 |
11:18 ET | 538 | 7.03 |
11:20 ET | 100 | 7.0761 |
11:22 ET | 100 | 7.105 |
11:24 ET | 567 | 7.07 |
11:26 ET | 2281 | 7.05 |
11:27 ET | 829 | 7.05 |
11:29 ET | 120 | 7.02 |
11:31 ET | 100 | 7 |
11:33 ET | 220 | 7.02 |
11:36 ET | 1240 | 7.0221 |
11:40 ET | 240 | 6.98 |
11:44 ET | 100 | 7.02 |
11:45 ET | 360 | 6.99 |
11:49 ET | 100 | 6.98 |
11:54 ET | 1783 | 7.015 |
12:00 ET | 420 | 7.02 |
12:05 ET | 1204 | 7.04 |
12:07 ET | 100 | 7.035 |
12:12 ET | 690 | 7.03 |
12:14 ET | 120 | 7.03 |
12:21 ET | 1100 | 7.03 |
12:23 ET | 200 | 7.025 |
12:32 ET | 100 | 7.035 |
12:36 ET | 1880 | 7.01 |
12:43 ET | 200 | 6.99 |
12:45 ET | 153 | 6.98 |
12:54 ET | 490 | 6.93 |
12:56 ET | 350 | 6.975 |
12:57 ET | 100 | 6.95 |
01:01 ET | 590 | 6.95 |
01:08 ET | 700 | 6.955 |
01:10 ET | 1295 | 6.95 |
01:14 ET | 480 | 6.93 |
01:21 ET | 2548 | 6.94 |
01:24 ET | 450 | 6.92 |
01:26 ET | 4499 | 6.96 |
01:28 ET | 210 | 6.98 |
01:30 ET | 626 | 6.99 |
01:35 ET | 2010 | 7.01 |
01:37 ET | 980 | 6.97 |
01:42 ET | 340 | 7.005 |
01:46 ET | 737 | 7 |
01:50 ET | 1400 | 7.04 |
01:57 ET | 200 | 7.075 |
02:00 ET | 124 | 7.04 |
02:02 ET | 490 | 7.04 |
02:09 ET | 480 | 7.04 |
02:15 ET | 1000 | 7.065 |
02:20 ET | 100 | 7.04 |
02:22 ET | 581 | 7 |
02:29 ET | 480 | 7 |
02:31 ET | 934 | 7 |
02:33 ET | 1400 | 7.02 |
02:40 ET | 225 | 7.039 |
02:44 ET | 480 | 7.01 |
02:49 ET | 590 | 6.98 |
02:54 ET | 680 | 6.985 |
03:00 ET | 300 | 6.97 |
03:02 ET | 745 | 6.98 |
03:03 ET | 546 | 7.02 |
03:12 ET | 1724 | 6.99 |
03:14 ET | 100 | 6.99 |
03:16 ET | 200 | 6.99 |
03:18 ET | 890 | 6.995 |
03:23 ET | 767 | 7.002 |
03:30 ET | 500 | 6.96 |
03:32 ET | 200 | 6.976 |
03:34 ET | 167 | 6.98 |
03:36 ET | 490 | 6.96 |
03:38 ET | 1000 | 6.97 |
03:39 ET | 990 | 6.965 |
03:41 ET | 800 | 6.97 |
03:43 ET | 200 | 6.97 |
03:45 ET | 1743 | 6.99 |
03:52 ET | 1020 | 7.03 |
03:54 ET | 300 | 7.0201 |
03:56 ET | 700 | 7.0201 |
03:57 ET | 1928 | 7.03 |
03:59 ET | 20392 | 7.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Candel Therapeutics Inc | 222.7M | -4.1x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.6x | --- |
Gossamer Bio Inc | 226.2M | -2.5x | --- |
Compass Therapeutics Inc. | 218.8M | -4.8x | --- |
Omeros Corp | 218.5M | -1.2x | --- |
Corbus Pharmaceuticals Holdings Inc | 228.7M | -3.2x | --- |
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $222.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.70 |
Book Value | $0.44 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.